Researchers are preparing to launch the SA leg of an international trial investigating whether the well-established measles, mumps and rubella (MMR) shot used in childhood immunisation programmes can protect front-line health-care workers from Sars-CoV-2, the virus that causes Covid-19.

More than 170 potential Covid-19 vaccines are being developed worldwide, but only nine are in late-stage phase 3 efficacy trials, and none has yet been approved by regulators, says the World Health Organisation. Researchers are thus also investigating whether tried-and-tested vaccines that provide protection from diseases as diverse as polio, tuberculosis and measles might provide a stopgap measure against Covid-19...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now